Huabio Therapeutics and Sungen Bio have entered into an exclusive, worldwide strategic partnership centered around a novel, as-yet-undisclosed tumor target. Their shared objective is to co-develop a potentially groundbreaking 'First-in-Class' antibody-drug conjugate (ADC) candidate. The two companies will pool their respective strengths and resources to propel this drug candidate into the clinical development phase, with the intended target indications spanning across multiple solid tumor domains.

The CEOs of Huabio Therapeutics and the Founder & CEO of Sungen Bio have both voiced their confidence and enthusiasm regarding the promising future of this collaborative endeavor. Huabio Therapeutics is primarily dedicated to pioneering innovative therapeutic solutions for liver diseases and cancers. On the other hand, Sungen Bio boasts specialized expertise in the development of cutting-edge ADC drugs, with its proprietary EZWi-Fit® platform technology standing out as a key differentiator, offering significant competitive advantages.